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ABSTRACT   
Objective: To assess the efficiency of alternative monitoring services for people with ocular 
hypertension (OHT), a glaucoma risk factor. 
Design: Discrete event simulation model comparing five alternative care pathways: treatment at OHT 
diagnosis with minimal monitoring; biennial monitoring (primary and secondary care) with treatment 
if baseline predicted 5-year glaucoma risk is ≥6%; monitoring and treatment aligned to National 
Institute for Health and Care Excellence (NICE) glaucoma guidance (conservative and intensive).  
Setting: UK health services perspective 
Participants:  Simulated cohort of 10,000 adults with ocular hypertension (Mean Intraocular Pressure 
(IOP) 24.9mmHg (SD 2.4).  
Main outcome measures: Costs, glaucoma detected, quality adjusted life years (QALYs). 
Results: Treating at diagnosis was the least costly and least effective in avoiding glaucoma and 
progression.  Intensive monitoring following NICE guidance was most costly and effective. However, 
considering a wider cost-utility perspective, biennial monitoring was less costly and provided more 
QALYS than NICE pathways, but was unlikely to be cost-effective compared with treating at 
diagnosis (£86,717 per additional QALY gained). The findings were robust to risk thresholds for 
initiating monitoring but were sensitive to treatment threshold, NHS service costs and treatment 
adherence.  
 
Conclusions: For confirmed ocular hypertension, glaucoma monitoring more frequently than every 
two years is unlikely to be efficient. Primary treatment and minimal monitoring (assessing treatment 
responsiveness [IOP]) could be considered, however further data to refine glaucoma risk prediction 
models and value patient preferences for treatment are needed. Consideration to innovative and 
affordable service redesign focused on treatment responsiveness rather than more glaucoma testing is 
recommended.  
 
(WORD COUNT 249)  
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INTRODUCTION 
Avoiding sight loss is a public health priority [1] but  decisions have to be made in terms of how best 
to manage eye care across competing demands. In the UK, about 24,000 people are newly registered 
with sight loss each year (blind and partial sight) with glaucoma being second to macular 
degeneration as the leading cause.[2,3] Although ocular hypertension is the main and only modifiable 
risk factor for glaucoma [4,5] organising a monitoring programme to monitor intraocular pressure 
(IOP) and detect early glaucoma has the potential to overburden health care and patients. Choices 
have to be made.   
 
The UK National Institute for Health and Care Excellence (NICE) clinical guideline for glaucoma[6] 
recommends long-term monitoring of ocular hypertension in specialist (health care professional 
accredited in glaucoma) led service either in secondary care (consultant led hospital eye service)  or 
primary care (community optometry) depending on local commissioning arrangements. Thresholds 
for initiating ocular hypotensive treatment are defined proportionate to glaucoma risk with 
stratification based upon the findings of a Markov economic model.[6] Recommended monitoring 
intervals were informed by a budget impact analysis and expert opinion. However, concerns were 
subsequently raised that glaucoma services are overburdened with monitoring low risk disease.[7]  
 
This study compares plausible alternative monitoring programmes for ocular hypertension (varying 
monitoring intervals, setting and treatment thresholds) to inform eye care policy in the UK. The study 
is part of a wider programme of work commissioned by the National Institute of Health Research, 
Health Technology Assessment programme to determine the optimum surveillance for people with 
ocular hypertension and is reported elsewhere in full. [8] 
 
METHODS  
We developed a discrete event simulation model[8] to assess the relative efficiency of monitoring a 
simulated cohort of 10,000 people with confirmed ocular hypertension (defined as an IOP>21mmHg 
and no clinical signs of glaucoma) in the UK.  We estimated cost-effectiveness (cost per glaucoma 
cases detected) and cost-utility (cost per incremental quality adjusted life year [QALY] gained) over 
20 years, adopting a NHS perspective and discounted costs and benefits at the recommended 3.5% 
discount rate. [9] All costs are reported in 2009-2010 Pound Sterling. The model structure is described 
in full elsewhere.[8]  
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In brief, we compared five care pathways: three ‘new’ care pathways and two based upon the existing 
NICE recommended pathways for ocular hypertension, i.e. guidance for current care, see table 1.  The 
three ‘new’ care pathways were (i) monitoring people with ocular hypertension biennially in 
secondary (consultant led eye care) or (ii) biennially in primary eye care (glaucoma trained 
community clinician [optometrist or General Practitioner] led care). In both ‘biennial’ pathways, 
ocular hypotensive treatment was modelled when the baseline risk of glaucoma was ≥6% based on a 
glaucoma five-year risk estimator. [10] For those requiring treatment, responsiveness was assessed at 
2 months and a <15% reduction in IOP prompted treatment escalation by adding a topical beta-
blocker. As an extreme alternative, we also modelled a pathway where for confirmed ocular 
hypertension (iii) treatment was initiated irrespective of glaucoma risk stratification with annual IOP 
monitoring by community optometrist. A <15% reduction in IOP prompted referral into secondary 
care with monitoring according to NICE OHT pathway.[6] The NICE monitoring guidance was 
summarised as (iv) an intensive pathway representing a monitoring interval between 4-12 months and 
(v) a more conservative pathway with monitoring intervals between 6-24 months. These two NICE 
informed pathways reflect variations in the recommended monitoring frequency in the NICE 
guideline.[6] The monitoring interval in both NICE pathways depended on baseline risk stratification 
based on age, IOP and central corneal thickness (CCT), factors regarded as predictors of glaucoma 
(see appendix table A1 for a detailed description of the NICE informed pathways included in our 
model). In all five pathways, if conversion to glaucoma occurred, subsequent care was in the hospital 
eye service according to the NICE glaucoma treatment guideline.[6] 
 
Table 1 Modelled care pathways for monitoring confirmed ocular hypertension 
Pathway Baseline risk stratification 
for treatment 
Treatment allocation Monitoring interval and 
type of monitoring  
(i) Biennial review - 
Primary care 
(Glaucoma 
accredited 
optometrist or 
General 
Practitioner) 
5-year glaucoma risk estimator 
[10] 
 
 
PGA initiated if 5 year 
glaucoma risk≥6%* BB 
added if <15% reduction in 
IOP  
Two yearly glaucoma 
assessment† [8] 
If IOP off target or 
conversion to glaucoma 
detected refer to secondary 
care 
(ii) Biennial review 
- Secondary care  
(Consultant led) 
5-year glaucoma risk estimator 
[10] 
 
 
PGA initiated if 5 year 
glaucoma risk≥6%. * BB 
added if <15% reduction in 
IOP 
Two yearly glaucoma 
assessment †[8] 
(iii)‘Treat all’  
IOP>21mmHg 
No further risk stratification 
PGA if IOP>21 mmHg  IOP monitoring once a 
year in primary care 
optometry and no 
glaucoma assessment. If 
IOP <15% reduction from 
baseline refer to hospital 
eye care according to NICE 
OHT guideline. [6] 
(iv) NICE NICE guideline (based on age, NICE guideline with NICE guideline. Using 
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informed-  NICE 
intensive 
CCT and IOP, see Appendix 
table A1) [6] 
modifications** [6] minimum intervals 
between monitoring 
visits[6]  
(v) NICE informed 
-  NICE 
conservative 
NICE guideline (based on age, 
CCT and IOP) [6] 
NICE guideline with 
modifications** [6] 
NICE guideline. Using 
maximum intervals 
between monitoring 
visits[6] 
IOP, Intraocular Pressure; PGA, prostaglandin analogue; CCT, Central Corneal Thickness 
* All those starting treatment, or requiring a treatment change have two consecutive (same day) IOP within two 
months of starting or changing treatment † IOP, perimetry and optic nerve assessment **People with CCT<555 
µm and on a PGA are treated until either 65years if 21mmHg<IOP≤25mmHg or 80 years if 
25mmHg<IOP<32mmHg.  Untreated low risk individuals, (CCT>590µm and IOP<32mmHg) with stable IOP, 
are not discharged in our model and this is a deviation from the NICE guideline. 
 
Apart from the ‘treat all’ pathway, each simulated individual within the model had a predefined 
glaucoma risk, which was based on the natural history of open angle glaucoma estimated from the 
distribution of predictors in a European derived population.[11] The mean age of the simulated 
population cohort was 57 years, with lower and upper inter quartile range limits of 51 and 64 
respectively, and mean IOP of 25 mmHg ranging from 21-36mmHg. The underlying distribution of 
IOP in the simulated cohort over time was estimated from predictions of a mixed linear regression 
model based on IOP data from an untreated ocular hypertension cohort and described in detail 
elsewhere.[8] The uncertainty due to measurement variability according to tonometer used was also 
included. [12] 
 
We populated the model with data from systematic reviews and statistical modelling estimates of the 
variability in IOP measurements and visual field indices[8] based on data from the placebo arms of 
two randomised controlled ocular hypertension treatment trials.[11,13] Details are described in table 
2. 
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Table 2 Model data (natural history, efficacy and diagnostic accuracy/agreement)  
Description Mean (years) 
Probability 
distribution* (mean, 
variance) Source 
Glaucoma progression†  
Time of progression from early 
glaucoma to moderate glaucoma 4 Normal (4, 2) 
Untreated. Variance based on 
assumption.[14]  
Time of progression from moderate 
to severe glaucoma 9 Normal (9, 2) 
Untreated. Variance based on 
assumption.[14] 
Time of progression from severe 
glaucoma to visual impairment 10 Normal (10, 2) 
Untreated. Variance based on 
assumption.[14] 
Treatment efficacy  
 
Mean IOP reduction 
(%) Source 
BB vs. no Treatment 12 
Developed based on weighted mean differences in NICE 
guideline[6] 
PGA vs. BB 5 
Developed based on weighted mean differences in NICE 
guideline[6] 
PGA + BB vs. PGA  1.5 
Developed based on weighted mean differences in NICE 
guideline[6] 
Treatment effectiveness (risk of glaucoma or progressive glaucoma) 
Reduction in risk of progression from any medical treatment (hazard ratio) 
Ocular hypertension  0.56 Maier et al 2007[15] 
Glaucoma 0.65 Maier et al 2005[15] 
Glaucoma surgery 
Proportion (of those converting to 
glaucoma) requiring 
trabeculectomy over 20years 
8.50% Burr et al 2012 [16] 
Proportion with successful 
trabeculectomy (success defined as 
no need for additional laser or 
surgery) 
88% at 1 year and 79% at 
year 4 
Burr et al 2012 [16]  
Measurement precision and accuracy of glaucoma detection 
Ophthalmologist   
IOP measurement error (mmHg) ‡ 1 
Based on regression model in Burr 2012. [8] 
Sampled from a normal distribution (mean, 0; 
variance,0.036)  
Sensitivity 1 
  
Assumption 
Specificity 1 
  
Assumption 
Primary care (optometrist or glaucoma specialist GP)  
IOP measurement error (mmHg) § 0  
  
Cook, 2012[12] Sampled from a normal 
distribution (mean 0; variance 5.76) 
Sensitivity 0.76 Azuara-Blanco 2007 [17] 
Specificity 0.93 Azuara-Blanco 2007 [17] 
* Probability distributions are used to simulate a hypothetical cohort of people with ocular hypertension; details are 
described in the text below. 
†Monocular visual field loss, mean deviation (MD in decibels (dB)) Mild glaucoma, 0.01 to -6.00dB; moderate glaucoma, -
6.01 to -12.0 dB; severe glaucoma, -12.01 to -20.00 dB; visual impairment -20.01 dB to worse. [18] 
‡ error term used in the model to reflect variability in IOP based on cohort data [8] 
§ error term used in the model to reflect inter observer error in tonometry [8][12] 
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Data on the adherence to treatment (eye drops) were sparse and varied widely. We assumed, based on 
expert opinion (three ophthalmologists) treatment adherence was 75% except for the ‘treat all’ 
monitoring pathways where we assumed lower adherence, 50%. Non-adherence was modelled as if 
untreated. Cost and utility data, see table 3, were derived from the British National Formulary (BNF) 
and data from 255 people with glaucoma[18] valued using UK population tariffs. We assumed that 
the score for those with ocular hypertension was the same as for mild glaucoma.   
 
Table 3: Costs and utility estimates 
 
Description Mean cost (£) 
 
Source  
Cost of monitoring 
Secondary care attendance 
IOP measurement only  90 
 
Information Services Division, NHS Scotland (Table R044X 
Specialty group costs for consultant –Ophthalmology- 
outpatients)  
Full glaucoma assessment  180 
 
Information Services Division, NHS Scotland (Table R044X 
Specialty group costs for consultant –Ophthalmology- 
outpatients)  
Primary care attendance 
IOP measurement only  10.35 
 
Assumption 
Full glaucoma assessment 20.7 
 
Department of Health. General Ophthalmic Services: NHS 
sight test fee  
Cost of treatment 
Beta blockers (£ per year of 
treatment) 18.72  
BNF based on Timolol non-proprietary, 0.5%, 5ml = £1.56. 
Assumed 1 bottle per month 
Prostaglandin analogues (£ per 
year of treatment) 149.76  
BNF based on Xalatan®, 2.5ml = £12.48. Assumed 1 bottle 
per month 
PGA + beta blockers  (£ per 
year of treatment) 171.84  
BNF based on Xalacom®, 2.5ml = £14.32. Assumed 1 bottle 
per month 
Glaucoma surgery 1479  NHS Reference Costs 2008-09 (HRG BZ18Z) 
European Quality of Life-5 Dimensions (EQ5D) utility weights 
Health state* Mean score  Source/note 
OHT 0.8015  Assumed equal to early glaucoma 
Mild glaucoma 0.8015  Burr 2007[18] 
Moderate glaucoma 0.7471  Burr 2007[18] 
Severe glaucoma 0.7133  Burr 2007[18] 
OAG visually impaired 
Visual impairment 0.535  Burr 2007[18] 
 
 
We addressed uncertainty by running one-way sensitivity analyses on a simulated cohort of 1000 
individuals. Sensitivity analyses included changing the following parameters in the biennial pathways: 
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(i) increasing the glaucoma risk threshold for initiating surveillance (e.g. from 6-50% as opposed to 
surveillance for all with confirmed ocular hypertension as in the base case); (ii) increasing the 
glaucoma risk threshold for initiating treatment (from ≥6% in the base case to a 50% 5-year predicted 
risk of glaucoma) to explore the effects of treating only a high risk group and (iii) changes to the unit 
price of treatment with a prostaglandin analogue (a. pricing at 50% of the value in table 3 and b. 
pricing prostaglandin analogue at beta blocker prices – table 3); (iv) varying the price of monitoring 
visits (exploring the upper and lower limits of the interquartile range  in the NHS reference costs) and 
(v) varying adherence from 50-20% for the ‘Treat all’ pathway and  75-95% for the more active 
monitoring pathways.  
RESULTS 
The baseline characteristics of the simulated individual characteristics are described in Table 4. 
Table 4 Simulated individual characteristics at start of the model, n=10,000 
 Variable 
Age 
(years) Initial IOP (mmHg) CCT (µm) PSD (dB) VCD ratio 
Mean 
(SD) 57 (9.8) 24.9 (2.4) 574.5 (31.7) 1.8 (0.3) 0.4 (0.2) 
Median 
(IQR) 57.1 (13.2) 24.6 (3.3) 574.2 (42.3) 1.8 (0.4) 0.4 (0.2) 
CCT: central corneal thickness; IOP: intra ocular pressure; PSD: pattern standard deviation; VCDR: vertical 
cup disk ratio; SD: standard deviation; IQR: inter-quartile range 
 
 
Over a 20-year time horizon the risk of converting to early glaucoma using the five monitoring 
strategies varied between 21-23%.  The ‘treat all’ pathway (ocular hypotensive drops initiated 
irrespective of glaucoma risk, annual IOP monitoring in primary care with referral to secondary care 
if IOP treatment response was inadequate) was the least costly and least effective in terms of number 
of people progressing to glaucoma, table 4. NICE intensive monitoring was the most effective in 
avoiding conversion to and progression of glaucoma but the most costly pathway.  Taking a broader 
perspective, by including quality of life, the differences in QALYS between any of the monitoring 
pathways are small as only a modest number of people in the cohort progress to any stage of 
glaucoma.  Biennial monitoring in secondary care is more costly but provides more QALYS than a 
‘treat all’ pathway. However the incremental cost-effectiveness ratio (ICER), in moving from the 
‘treat all’ pathway to biennial monitoring in secondary care, of around £87,000 is much larger than 
the usual maximum threshold of willingness to pay (WTP) for a QALY adopted by NICE in 
considering implementation of new policies (£20-30,000 per QALY gained). [9] 
 
 
 
 
Table 5 Clinical effectiveness and cost-utility analysis  
 
Clinical effectiveness of alternative monitoring pathways.   N=10,000 
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Pathway 
Converted to 
glaucoma (n) 
Progressed to moderate 
glaucoma (n) 
Progressed to 
severe glaucoma 
(n) 
Treat all (annual IOP only) 2282 1708 468 
Biennial monitoring (secondary care) 2073 1536 343 
Biennial monitoring (primary care) 2114 1545 365 
NICE conservative 2079 1528 349 
NICE intensive 2060 1507 336 
 
Incremental cost, QALYS and incremental cost per QALY gained (ICER) 
 
Pathway 
Average 
Total Cost 
(£) 
Incremental 
cost (£) 
Average 
Total 
QALY 
Incremental 
QALYs ICER (£) 
Treat all 3393 9.7866 
Biennial monitoring 
(secondary care) 3956 562 9.7932 0.0066 85,312 
Biennial monitoring 
(primary care) 4696 740 9.7920 Dominated Dominated 
NICE conservative 5087 391 9.7923 Dominated Dominated 
NICE intensive 6862 1,776 9.7931 Dominated Dominated 
*dominated, more costly and less effective than another alternative 
 
A summary of the findings of the sensitivity analyses is presented as on line supplementary material 
(Appendix 2). The results were not sensitive to varying the risk threshold for initiating surveillance 
(6-50%) but were sensitive to increasing the threshold for treatment. When the treatment threshold 
was increased to a 5-year glaucoma risk of 15% the biennial monitoring pathway (secondary care) 
dominated the ‘treat-all’ pathway (less costly and resulted in more QALYs). Sensitivity analyses 
around unit costs of treatment did not change the ICERs substantially. Varying the unit price of 
treatment with a prostaglandin analogue reduced the average costs for all pathways particularly those 
that involved more treatment (‘treat all’) but as expected no effect was observed on QALYS as only 
the unit costs of treatment changed.   
 
The findings of the base case analysis were sensitive to varying unit costs for health care visits for a 
glaucoma-monitoring visit (including perimetry) and visits to measure IOP in response to treatment. If 
the unit cost of hospital visit was reduced from the base case value (£180) to £73 and an IOP only 
visit from £90 to £51, biennial monitoring in secondary care was cost effective compared with a 
‘treat-all’ pathway, ICER £10,857 per QALY gained.  Retaining the hospital glaucoma assessment at 
base case level (£180) but reducing the costs of an IOP visit, if the unit cost of an eye care visit was 
£50-55, biennial monitoring in secondary care was cost effective, ICER £11,410 per QALY gained.   
 
The results were also sensitive to varying the estimated adherence to ocular hypotensive treatment. 
When adherence decreased for a ‘treat-all ‘pathway the cost effectiveness of biennial monitoring 
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improved, e.g. assuming a 30% adherence in the ‘treat all’ pathway and 75% adherence in a biennial 
pathway the ICER is £26,334.  
 
DISCUSSION  
We modelled less intensive pathways than recommended in the current NICE glaucoma guideline[6] 
to explore optimal treatment thresholds and monitoring intervals for people with ocular hypertension. 
Additionally, we used findings from statistical models of cohort data to inform an individual’s risk 
stratification and the frequency of monitoring in our biennial monitoring pathways. These data were 
not available when the NICE clinical guideline was developed. Although effective at reducing the 
incidence of glaucoma, based on this study’s findings, pathways based on current NICE 
recommended pathways are unlikely to be cost-effective from a UK policy perspective compared with 
the alternative approaches we explored. Initiating treatment as soon as ocular hypertension is 
identified with minimal monitoring once the target IOP is reached is the least costly approach and 
compared with the alternative pathways modelled could be seen as the most cost-effective (balancing 
cost and QALYs gained).  Alternatively, based on the sensitivity analyses, initiating treatment if the 
5-year glaucoma risk was >10%, minimising the cost of repeat eye care visits and supporting patient 
adherence to treatment, with subsequent glaucoma tests every two years could be an efficient 
approach for surveillance of ocular hypertension. There are uncertainties regarding the optimal 
glaucoma risk threshold for initiating treatment, service costs, and long-term adherence to medication.  
The impact of any treatment side effects may not be fully captured in QALY estimates. 
 
These findings should be interpreted bearing in mind the limitations of the data available to populate 
the model.  In particular, natural history data represented ocular hypertensive populations included in 
randomised controlled trials and are not necessarily generalisable to those with ocular hypertension 
presenting to routine eye care services.   
 
We used a discrete event simulation model, which simulates the costs and consequences of individual 
patients, enabling disease modelling and event complexities that are difficult to model in simpler more 
commonly used modelling approaches such as decision tree or Markov models. In any modelling 
exercise there are uncertainties in model structure, i.e. are the care pathways modelled appropriate, 
parameter uncertainty regarding the data used and time horizon of the model? We used recommended 
best practice methods to ensure validity of the model. This included extensive validation and 
calibration exercises.  As part of the model implementation process we verified, validated (to verify 
the model fits the empirical data) and calibrated the model where needed. We simulated individual 
characteristics for a population of 1000 people at the point where they enter into the model.  The data 
were interpreted alongside data from the literature to judge face validity. [11]. In addition, we ran the 
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model for shorter time horizons and confirmed that glaucoma conversion was consistent with the 
literature.[10,19]  
 
We developed the care pathways using the NICE glaucoma guideline as a representation of current 
recommended practice for managing ocular hypertension. This may not reflect actual practice around 
the UK but was a standardised comparator. We developed two pathways capturing the extremes of the 
NICE recommended pathways, based on these extremes the cost-effectiveness of anything in between 
could be inferred. As there is limited capacity in hospital eye care services, we developed alternative 
pathways to test whether less intensive monitoring would be a cost-effective option for a national 
health service. These alternative monitoring scenarios were developed in consultation with 
ophthalmologists, nurses, patients and the public[8] and a recent economic evaluation in the 
Netherlands that suggested that a treating ocular hypertension irrespective of glaucoma risk was a 
cost-effective approach in a Dutch context. [20] As neither of the extreme scenarios based on NICE 
were cost-effective compared with minimal glaucoma monitoring it is unlikely that any other strategy 
consistent with NICE guidance would be cost-effective. However it should be noted that the original 
version of the model did not allow for people deemed at low risk of developing glaucoma 
(CCT>590micrometres and IOP<32mmHg) to be discharged after having a stable IOP for more than 3 
years. We added this condition in a subsequent model development and the base case results reported 
in Table 5 remain robust. Discharged individuals move to yearly check-ups at a community 
optometrist and while the NICE informed strategies become, on average, less costly, they are not cost-
effective compared with the other modelled strategies.  
 
 
We used data from systematic reviews of glaucoma risk prediction tools and statistical models 
determining the optimum frequency of monitoring IOP to detect true change from measurement noise 
to populate the model. For the statistical model we used serial measures of IOP and explored visual 
field data from the placebo group of randomised controlled treatment trials [11,13] which may not be 
representative of variability in the general population. Repeat measures of visual fields were sparse in 
these trial data thus the model estimates were based solely on IOP data. It should be noted, however, 
that in the trial cohorts the visual fields (mean deviation) showed no true change over four years.[8]  
 
We characterised the risk of developing glaucoma using a glaucoma 5-year risk estimator[21] and 
applied this risk prediction model to the simulated cohort. This glaucoma risk model has good 
predictive utility for estimating the 5-year risk of open angle glaucoma in an external validation 
study.[19] It is available as an online tool and may be easier to use in clinical practice than risk 
stratification based on age, CCT and IOP as in the NICE guideline although this has not been 
evaluated as far as we are aware. In two of our ‘new’ pathways, ocular hypotensive treatment was 
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initiated if the predicted 5-year risk of glaucoma was ≥ 6%. This cut-off was based on the Ocular 
Hypertension Treatment Study cohort where low glaucoma five-year risk was defined arbitrarily as 
<6%, moderate as 6-13% and high-risk as >13%. [22] 
 
We took a 20-year time horizon, which might not be sufficiently long to fully capture the impact on 
vision in a condition (i.e. glaucoma) that is slowly progressive for most people. We chose this horizon 
as extrapolating 5-year effectiveness data to even longer time horizons would be questionable. If we 
had taken a lifetime horizon more cases of visual impairment would have occurred, but given the time 
it takes to develop visual impairment, discounting would have reduced their impact on any differences 
between alternative pathways.  
 
A similar evaluation was conducted in the Netherlands, investigating direct treatment initiation in 
ocular hypertension evaluated from a societal perspective with a lifetime horizon.[20] Direct pressure 
lowering treatment was less costly and more effective than a strategy of delaying treatment until early 
signs of glaucoma are apparent. The uncertainty surrounding the model parameters did not affect the 
conclusions. In the Dutch model adherence to treatment was not taken into account as it was assumed 
that it was an implicit part of the treatment effectiveness estimates. However, these estimates were 
from selected trial populations where adherence may be greater than in clinical practice..  We 
explored varying adherence based on published estimates, [23–25] further data would reduce the 
uncertainty in our findings.  
 
Findings were also sensitive to the costs of repeat visits to assess treatment responsiveness (IOP) but 
were not sensitive to medication costs. For community monitoring we used a cost of £20.70 based 
upon the NHS sight test tariff.  Should this cost be too low, for example should additional charges be 
incurred for the use of additional tests, then a higher cost would make community monitoring even 
less cost-effective than the base case results indicate. 
 
In summary, we find no clear benefit in terms of cost-effectiveness from intensive monitoring of 
people with ocular hypertension to detect glaucoma. Innovative restructuring of the ophthalmic 
service, which is less costly and has greater emphasis on treatment responsiveness rather than more 
glaucoma testing is recommended. The feasibility of alternative and more affordable monitoring 
pathways should be explored. A rigorously designed prospective comparative study comparing low 
intensity surveillance (incorporating alternative treatment thresholds) with current practice is 
recommended.  
 
Data sharing: All authors agree to allow review of the data by British Journal of Ophthalmology 
upon request from the corresponding author. 
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Appendix 1 
 
Table AI Treatment and monitoring pathways developed from the NICE guideline. [6] 
Treatment allocation criteria (NICE informed pathways: NICE intensive and NICE conservative)* 
CCT >590 µm 555-590 µm <555 µm Any 
Untreated 
IOP 
(mmHg) >21 - 25 >25 - 32 >21 to 25 
>25 to 
32 >21 to 25 >25 to 32 >32 
Age (years) Any Any Any 
Treat 
until 60 
Treat until 
65 
Treat until 
80 Any 
Initial 
treatment 
No 
treatment 
No 
treatment 
No 
treatment BB PGA PGA PGA 
Monitoring intervals 
NICE intensive  
IOP only N/A N/A N/A 
At 2 
months 
At 2 
months 
At 2 
months 
At 2 
months 
Full 
assessment* 
Every 12 
months 
Every 6 
months 
Every 6 
months 
Every 6 
months 
Every 4 
months 
Every 4 
months 
Every 4 
months 
NICE conservative  
IOP only N/A N/A N/A 
At 2 
months 
At 2 
months 
At 2 
months 
At 2 
months 
Full 
assessment 
** 
Every 24 
months 
Every 12 
months 
Every 12 
months 
Every 
12 
months 
Every 6 
months 
Every 6 
months 
Every 6 
months 
NA, not applicable; BB, beta-blockers; PGA, prostaglandin analogue. IOP, Intraocular pressure; 
CCT, Central Corneal Thickness 
*Untreated individuals and deemed at low risk of glaucoma conversion (CCT>590µm and 
IOP<32mmHg) are not discharged and this is a deviation from the NICE guideline. 
** Full assessment: IOP and assessment of the optic nerve head, and visual fields.   
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Appendix 2    One-way sensitivity analyses results (discounted) 
*Scenario Change Strategy Cost QALY Incremental cost per QALY (£) 
Risk threshold for initiating 
treatment 
10% Treat All 3412 9.7757  
Biennial (secondary care) 3631 9.7812 39,701 
Biennial (primary care) 4379 9.7807 dominated 
NICE informed, conservative 5156 9.7813 15,022,678 
NICE informed, intensive 6879 9.7828 1,175,663 
15% 
 
 
 
 
Biennial (secondary care) 3311 9.7805  
Treat All 3412 9.7757 dominated 
Biennial (primary care) 4118 9.7802 dominated 
NICE informed, conservative 5156 9.7813 2,213,752 
NICE informed, intensive 6879 9.7828 1,175,663 
 50% reduction in hospital 
costs of glaucoma 
assessment visit  
Full assessment visits (with 
perimetry) = £73; IOP only = 
£51 
Treat All 2736 9.7757  
Biennial (secondary care) 2814 9.7828 10,857 
NICE informed, conservative 3120 9.7813 dominated 
Biennial (primary care) 3180 9.7826 dominated 
NICE informed, intensive 3861 9.7828 dominated 
Variation in cost of visits to 
measure IOP 
£51 
Treat All 3188 9.7757  
Biennial (secondary care) 3270 9.7828 11,410 
Biennial (primary care) 3856 9.7826 dominated 
NICE informed, conservative 4381 9.7813 dominated 
NICE informed, intensive 6075 9.7828 dominated 
£65 
Treat All 3269 9.7757  
Biennial (secondary care) 3523 9.7828 35,641 
Biennial (primary care) 4107 9.7826 dominated 
NICE informed, conservative 4659 9.7813 dominated 
NICE informed, intensive 6364 9.7828 dominated 
Adherence for non-
monitoring 
pathway 
('Treat All') 
 50% 
Treat All 3412 9.7757  
Biennial (secondary care) 3974 9.7828 78,911 
Biennial (primary care) 4555 9.7826 dominated 
NICE informed, conservative 5156 9.7813 dominated 
NICE informed, intensive 6879 9.7828 dominated 
30% 
Treat All 3635 9.7699  
Biennial (secondary care) 3974 9.7828 26,334 
Biennial (primary care) 4555 9.7826 dominated 
NICE informed, conservative 5156 9.7813 dominated 
NICE informed, intensive 6879 9.7828 dominated 
Adherence for monitoring 
pathways 
75% 
Treat All 3412 9.7757  
Biennial (secondary care) 3974 9.7828 78,911 
Biennial (primary care) 4555 9.7826 dominated 
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NICE informed, conservative 5156 9.7813 dominated 
NICE informed, intensive 6879 9.7828 dominated 
90% 
Treat All 3412 9.7763  
Biennial (secondary care) 3715 9.7868 28,723 
Biennial (primary care) 4506 9.7865 dominated 
NICE informed, conservative 4864 9.7863 dominated 
NICE informed, intensive 6646 9.7879 2,678,852 
 
* Results for all thresholds are reported in the health technology assessment monograph, surveillance for ocular hypertension: an evidence synthesis and economic evaluation. [8] 
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